Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. For both perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA), 5-year overall survival of about 30% has been reported in large series. This review addresses several challenges in surgical management of cholangiocarcinoma. The first challenge is diagnosis: a biopsy is typically avoided because of the risk of seeding metastases and the low yield of a brush of the bile duct.
| INTRODUC TI ON
Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. Cholangiocarcinoma can arise anywhere along the biliary tree. Intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) cholangiocarcinoma differ in tumour characteristics and each has a separate American Joint Committee on Cancer (AJCC) staging system. 1,2 Consequently, they require a different treatment approach. dCCA is beyond the scope of this review because diagnostic work-up and treatment are more similar to cancer of the head of the pancreas.
Most patients with cholangiocarcinoma are ineligible for surgical resection because of metastatic or locally advanced disease at the time of presentation. Only about one in five patients with pCCA is eligible for surgery at the time of presentation. 3 Therefore, even high-volume Western centres rarely perform more than two resection per month for pCCA. 4, 5 The main goal of surgery for cholangiocarcinoma is a complete (R0) resection with low post-operative mortality. This goal requires a multidisciplinary team with dedicated radiologists, interventional radiologists, endoscopists, anaesthesiologists, intensivists, hepatologists, pathologists and hepatobiliary surgeons with both surgical oncology and vascular or transplant skills. Outcomes are best in high-volume centres.
6
The aetiology, pathogenesis, risk factors and epidemiology of cholangiocarcinoma are reviewed in separate contributions in this issue. The aim of this review is to summarize the diagnostic work-up and treatment of patients with resectable pCCA or iCCA.
| PERIHIL AR CHOL ANG IOC ARCINOMA

| Diagnostic work-up
In this review, we focus on the diagnostic work-up pertaining to surgical treatment options (ie, resection and liver transplantation). The diagnosis pCCA continues to pose a challenge. The early symptoms are non-specific; abdominal discomfort or pain, anorexia and weight loss. Most patients present with a high serum bilirubin. Sometimes patients complain of pruritus, which may precede jaundice by a few weeks. In some patients, pCCA is incidentally discovered because of abnormal liver function tests. 7 The main goal of the diagnostic work-up is not only to confirm the presence of cancer, but also to assess the extent of bile duct involvement, vascular involvement (portal vein and the branches, hepatic proper artery and the branches) and distant metastases. It is crucial to perform all imaging before biliary drainage, because ascertainment of the biliary and vascular extent of pCCA is more challenging after endoscopic stent placement. Moreover, the extent of the tumour determines the future liver remnant (FLR), which determines the segments to be drained (see also section on biliary drainage).
Initial US examination shows intrahepatic biliary tree dilatation, typically without dilatation of the gallbladder and the common bile duct. CT of the chest and abdomen is the standard modality for staging and assessment of vascular involvement. MRI with MRCP and diffusion-weighted imaging can be of additional value to assess the biliary extent of the tumour. Positron emission tomography (PET) CT should not be routinely used in the diagnostic work-up because of low sensitivity and specificity. However, in selected patients (eg, with increased surgical risk or more advanced disease), PET CT may be justified with a 10% yield of occult metastatic disease. 9, 10 Studies comparing imaging modalities are sparse.
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The diagnosis of pCCA requires the presence of a malignant appearing stricture in the liver hilum and at least one of the following: 
Key points
• Pathological confirmation before surgery is not mandatory in patients with cholangiocarcinoma.
• All imaging for cholangiocarcinoma must be performed before biliary drainage. After drainage it is harder to determine resectability.
• Preoperative biliary drainage may do more harm than good in patients with an FLR above 50%. A hepatobiliary surgeon experienced with cholangiocarcinoma should be consulted prior to biliary drainage.
• Portal vein embolization (PVE) is recommended in patients with an FLR of less than 40%.
• Multiple tumors and positive lymph nodes are poor prognostic factors for iCCA, but do not preclude 5-year survival after resection.
the bile duct or hepatoduodenal lymph nodes (eg, colorectal cancer).
In about 15% of patients who underwent a resection for apparent pCCA, final pathological examination found benign disease.
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| Indication to resection
Given that surgery provides the only chance for cure of pCCA, hepatobiliary resection is indicated when it is both anatomically and physiologically feasible. The goal for surgery is to achieve an R0 resection while preserving adequate vascular inflow to and function of the FLR. This can be very difficult, given the localization of these tumours in the hepatic hilum in intimate relation with the portal vein and hepatic artery.
pCCA is typically stratified according to the Bismuth-Corlette based on the biliary extent of the tumour 14 and the AJCC classification systems 1 that considers local (biliary and vascular) and distant tumour extent. The Blumgart system also considers hepatic lobar atrophy. 15 Regardless of the staging system, it is difficult to accurately evaluate resectability preoperatively, and the definitive decision to resect or not is made at surgical exploration. For example, the biliary extent of the tumour towards the segmental bile ducts is often more extensive at final pathology, than judged on preoperative imaging.
In the majority of patients, radical surgical resection of pCCA requires an (extended) hemi-hepatectomy, and not only the patient's functional status (ie, co-morbid conditions, nutrition, performance status) but also the volume and function FLR needs to be considered. Traditionally, a "safe" liver resection has been considered one leaving an FLR of at least 25% of the preoperative liver volume in patients with normal liver parenchyma or at least 30% to 40% in livers that are compromised by steatosis, chronic cholestasis, cirrhosis or chemotherapy. 16, 17 FLR function can be assessed more formally by examining hepatocellular uptake and excretion (indocyanine green clearance), uptake and biotransformation ( 13 C-methacetin breath test, LiMAx), and uptake (hepatobiliary scintigraphy). These function tests can be combined with SPECT-CT to differentiate functional from non-functional liver tissue. 18 When the FLR is insufficient, strategies to increase the FLR should be considered (see sections below on portal vein embolization).
| Preoperative biliary drainage
Obstructive cholangitis is an absolute indication for preoperative biliary drainage (PBD). In the absence of cholangitis, PBD of the FLR is debated, because it may cause cholangitis that is associated with post-operative liver failure and mortality. The indication for PBD must therefore be cautiously evaluated by a hepatobiliary multidisciplinary team.
Obstructive jaundice is associated with a pro-inflammatory state. 19 Some series reported an association between serum bilirubin and post-operative complications, 20, 21 and the authors therefore advocated routine PBD. However, a randomized controlled trial (RCT) for patients with periampullary tumours found an increase in perioperative complications after PBD. 22 Consequently, patients with resectable dCCA and a bilirubin level below 15 mL/dL should undergo a pancreatoduodenectomy without preoperative biliary drainage. Because liver resection in jaundiced patients was judged at higher surgical risk, most surgeons continued PBD in jaundiced patients with pCCA. 6 Several retrospective studies reported that PBD is associated with infectious complications, and cholangitis is an independent prognostic factor for post-operative mortality. 23, 24 Another drawback of PBD is the risk of clinical deterioration or progressive disease because of complications secondary to PBD in about 15% of pCCA patients.
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In pCCA patients with an insufficient FLR (ie, below 40%), PBD of the FLR is required prior to portal vein embolization (PVE), because biliary obstruction impairs liver regeneration. For patients with a FLR volume above 50% (eg, requiring a left hemihepatectomy), the risk of cholangitis and related mortality after drainage does not justify the potential benefit of biliary decompression. 4, 24 Two procedures to drain the bile ducts are available: percutaneous transhepatic biliary drainage (PTBD) and endoscopic biliary drainage (EBD). Two recent meta-analyses, found a higher procedure conversion, cholangitis and pancreatitis rate in the EBD group without showing differences in post-operative complications and survival. 25, 26 A recent RCT comparing PTBD to EBD was stopped for excess mortality in the PTBD group (41% vs 11%), whereas severe preoperative drainage-related complications were comparable in the two populations. However, the sample size of this study was small (27 patients per arm). 27 To overcome the morbidity of EBD, endoscopic nasobiliary drainage (ENBD) has been proposed in Japan. They report a lower rate of conversion to PTBD. 28 Others failed to show differences when comparing ENBD with EBD and PTBD. 29 Among the drawbacks of ENBD are the patient discomfort and the possibility of accidental dislodgment. Because cholangitis is the main source of morbidity of PBD, the placement of a PTBD above the ampulla has been advocated to reduce bacterial contamination. 30 Dislocation of the tip of the PTBD proximal to the tumour is a challenging complication of this strategy.
Based on the current evidence, a reasonable approach would be to perform drainage of the FLR only in patients presenting with cholangitis as well as in patients with both a bilirubin level exceeding 4 mL/dL and an FLR below 40%. Drainage of the contralateral liver is reserved for those patients with persistent jaundice and/or sepsis. In the absence of large RCTs, there is no definitive evidence to recommend PTBD, EBD or ENBD.
| Portal vein embolization and ALPPS
An inadequate FLR volume and function poses the patient at risk to post-hepatectomy liver failure (PHLF). PVE aims to decrease the risk of PHLF by occluding the portal vein to the side of the liver that is resected, causing hypertrophy of the FLR. 31, 32 In two systematic reviews, preoperative PVE was associated with a relative increase in FLR of about 40% and a 2.5% adverse events rate. 31, 32 A more recent review details the four largest studies on PVE for pCCA, conducted in a total of 586 patients. [33] [34] [35] [36] [37] Only one patient died because of PHLF.
No consensus on the optimal FLR cut-off to perform PVE exists. 33 In most studies, cutoffs of the FLR range from 20%-40%, sometimes in combination with assessment of indocyanine green clearance. 33 
| Approach to resection
The majority of patients with pCCA require an (extended) hemi-hepatectomy with resection of the extrahepatic bile duct ( Figure 1 ). Right trisectionectomy has the advantage of a greater length of the left hepatic duct (2-3 cm) as opposed to the right duct (<1 cm). 43 En-bloc resection of the caudate lobe is recommended because the tumour typically extends into the caudate lobe via small branches draining into the right or left hepatic ducts or the biliary confluence. 44 
For
Bismuth IIIB tumours, a left hepatectomy or trisectionectomy extended to second-order biliary radicals is needed, often requiring reconstruction of multiple right-sided ducts. 45 dCCA (ie, located in the intrapancreatic bile duct), is treated with a pancreatoduodenectomy.
Resection of only the extrahepatic bile duct may be considered for Bismuth I pCCA, especially in frail patients. However, in a study of patients with Bismuth I or II tumours, 5-year survival was 30% with extrahepatic bile duct resection alone vs 50% with en-bloc liver resection. 46 Lymphadenectomy of locoregional lymph nodes in the hepatoduodenal ligament is recommended, but has a bigger impact on staging than on improving survival. Portal vein resection and reconstruction may be required and may improve resection rates, R0 resection rates and survival. 6, 47 Hepatic artery resection and reconstruction has also been reported, though morbidity and mortality rates can be high and survival with main or unilateral hepatic artery involvement is poor. 48 preoperative CRT has proved to be safe and seems to enhance R0 resection rate for (borderline) unresectable pCCA. Definitive data from the NACRAC study are awaited to determine whether neoadjuvant CRT also improves survival (UMIN000000992 and UMIN000001754).
With regards to the role of adjuvant treatment for pCCA, more studies are available. Firstly, a large Japanese RCT, including 118 patients with cholangiocarcinoma, had failed to demonstrate a better OS for patients (n = 58) treated with mitomycin and 5-FU after surgery, compared to the controls (n = 60) who had not received any adjuvant treatment. 55 Later studies found an improvement in OS after adjuvant treatment, especially for patients with positive lymph nodes. 56, 57 In particular, in a cohort of 260 patients who underwent R0/R1 resection for pCCA, Kang reported a statistically significant survival benefit with 5-FU-based adjuvant regimen for patients with positive lymph nodes. 58 This result has recently been confirmed on multivariate analysis by a multicentre retrospective study of 249 patients after curative resection for pCCA. 59 Most adjuvant RCTs include all patients with biliary tumours. These RCT show conflicting results as discussed below in the section on iCCA.
| Outcomes after resection
Outcomes for patients with resectable pCCA depend on three factors:
1. Tumour characteristics: local extent of the tumour, tumour differentiation, lymphovascular, perineural and/or microvascular invasion, lymph node involvement and the presence of distant metastasis.
2. Whether or not a patient is considered for resection at a multidisciplinary meeting including experienced hepatobiliary surgeons.
3. The surgical approach aiming at a radical (R0) resection, and perioperative morbidity and mortality.
The reported 3-and 5-year survival rates after resection for pCCA are around 45% (35 to 60%) and 30% (15 to 40%). 6, 36, 60, 61 Most patients are not cured after resection for pCCA; about 80% will develop recurrent disease mostly within two years after surgery. Their impact, however, mostly disappears in multivariable analysis, adjusting for R status, nodal involvement and tumour differentiation.
Several nomograms predicting prognosis have been devised.
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The early post-operative (procedure-related) mortality is around 10% in large Western centres, but may vary considerably from 2% to 15%. 4, 5, 24 Italian and French multicentre studies both found a postoperative mortality of about 10%. Nagino reports a mortality of 11% before 1990 and 1.4% after 2005. 6 Common serious complications are PHLF, biliary complications, infectious complications and vascular complications.
In an attempt to improve the R0 resection rate, more extensive resections have been proposed. One type of extended resection for pCCA is combining liver resection with a pancreatoduodenectomy, particularly in patients in whom the tumour extends towards the distal bile duct. Post-operative mortality and long-term survival are favourable in high-volume centres, but poor in less experienced centres.
Many publications have shown that both the R0-resection rates and post-operative mortality rates depend strongly on the experience of the centre. 66, 67 These results clearly argue for performing surgery in patients with pCCA only in highly experienced centres.
However, about 25% of patients will have an R1 resection, even in experienced centres. Only a liver transplantation (LT) could reassure an R0 resection in these patients.
| Liver transplantation
The rationale of LT in patients with pCCA is to avoid two unfa- The Mayo Clinic protocol (Table 1) for patients with unresectable pCCA, introduced in the 1993 (based on a previous University of Nebraska study), represented a breakthrough. 72 The protocol consists of external beam radiation (40-45 Gy) followed by transcatheter radiation (20-30 Gy) with iridium wires, intravenous 5-flurouracil administered for chemosensitization during radiation therapy, and capecitabine administered afterward while waiting LT. 73, 74 Staging surgery with lymph node biopsies is performed after brachytherapy.
The reported intention-to-treat survival rates at 1, 3 and 5 years were 82%, 62% and 56% respectively. The overall survival after LT at 1, 3 and 5 years was 91%, 81% and 74% respectively. 75 These favourable data were subsequently reproduced in a multicentre study including 12 high-volume centres in the US. 76 The 5-years intentionto-treat survival was similar (53%). Notably, more than two-thirds of the patients had PSC as underlying disease, compared to about 5% in other pCCA cohorts.
Whether the results of the Mayo Clinic series are because of careful selection of the patients enrolled or to the efficacy of the pretransplant therapy is still debated. In a retrospective study,
Mantel identified 28 patients with pCCA who met the strict selection criteria for the Mayo Clinic protocol but had not undergone neo-adjuvant chemoradiation therapy. 77 Five-year survival in this subgroup was 59%, which is comparable to the results obtained in the Mayo series.
A further criticism to the results of Mayo protocol is that in the case of a patient with a negative cytology, negative FISH, and no residual tumour in the specimen after transplant the question remains whether the patient ever had a cancer. The authors estimate this possibility to be about 15% of patients. 78 However, the high risk of recurrence after transperitoneal biopsy justifies this approach at least until new and more accurate diagnostic techniques are developed.
Ethun et al reported that patients resected for pCCA and meeting transplantation criteria had a significantly worse 5-year survival compared to patients who received LT (18% vs 64%). 68 Among patients who underwent resection for tumours smaller than 3 cm with node-negative disease, and after excluding PSC patients, transplant was still associated with improved OS (5-year: 54% vs 29%; P = 0.03).
Prioritization to LT for pCCA patients is one of the most debated 1-3) every 3-4 weeks for six courses followed by oral capecitabine until progression. 82 They reported prolonged survival in those patients with periductal infiltrating pCCA rather than in those with mass-forming pCCA. The overall toxicity was mild. In this study, there was no a control group, thus limiting the generalizability of the conclusions.
Irreversible electroporation (IRE) is a promising image-guided
ablation technique based on short-pulsed high-voltage current fields that destroy the cell membrane, then altering the intracellular compartment leading finally to cell apoptosis. 83 The non-thermal physical mechanism implies the absence of the heat/cold-sink effect and of the damage to adjacent structures (ie, portal vein and hepatic artery). This is the main advantage of IRE over other ablative procedures, such as microwave and radiofrequency ablations. 
| Future research
Future research should aim to increase the R0 resection rate. This can be achieved by more extensive resection, particularly of the proximal bile ducts. The best option to achieve that aim is liver transplantation. To evaluate LT for pCCA, a prospective study has just been initiated in Germany (pro-duct002 trial, DRKS00013276). Finally, reducing perioperative morbidity and mortality is an important goal to improve outcome of surgery. To achieve that, pCCA patients should be treated only in experienced centres after referral prior to drainage.
| INTR AHEPATI C CHOL ANG IOC ARCINOMA
| Diagnostic work-up
Intrahepatic cholangiocarcinoma (iCCA) arises in the biliary tree, proximal to the second-order bile ducts. Most iCCA patients are diagnosed with a large mass on imaging after presenting with unspecific complaints including abdominal pain, weight loss and fatigue.
About 15% of patients present with jaundice caused by biliary obstruction. Imaging in iCCA patients presenting with jaundice shows a large mass (ie, >3 cm) that has grown towards the liver hilum. This should be distinguished from pCCA patients showing a smaller mass arising from the biliary confluence or main hepatic ducts. iCCA can also be diagnosed in an asymptomatic patient who underwent imaging for elevated liver enzymes or a reason unrelated to iCCA.
The majority of iCCA patients have no underlying liver disease.
Underlying liver disease, however, is a risk factor for iCCA. Patients with cirrhosis in a screening programme for early detection of HCC are sometimes found to have iCCA. Especially small iCCA may be difficult to distinguish from HCC on imaging. Sometimes, the final diagnosis is only made at pathological examination after surgical resection or liver transplantation.
Serum tumour markers play a modest role in the diagnostic workup. CA19-9 is elevated in most patients with iCCA. About 10% of patients cannot synthesize CA 19-9, and CA 19-9 elevation can also be attributed to biliary obstruction. Elevated alpha-foetoprotein (AFP)
is more likely in patients with HCC. Serum IgG4 is elevated in patients with auto-immune cholangitis, which may sometimes present as an intrahepatic mass. 90 However, not all patients with elevated
IgG4 have auto-immune cholangitis and patients with elevated
IgG4 may also have cancer. Sensitivity and specificity are improved when measuring the IgG4/IgG RNA ratio. 91 Many of these patients had long-term exposure to solvents, oil products and other organic agents. A biopsy or a course of steroids should be considered in these patients. Some patients have a patient history or imaging consistent with another autoimmune disease such as autoimmune pancreatitis.
A high quality tri-phasic CT is the standard imaging for iCCA for both diagnosis and surgical planning. iCCA typically shows early ar- 
| Indication for resection
The decision for surgical resection of iCCA requires a trade-off between anticipated oncological benefit (ie, superior OS and quality of life) vs surgical risk (ie, post-operative mortality and morbidity). 
| Approaches to resection
The aim of resection for iCCA is similar to any oncological liver resec- Staging laparoscopy should be considered in all patients with iCCA to rule out occult metastastic disease. This risk is particularly high in patients with high CA 19-9, major vascular invasion and suspicious lymph nodes. 99 Exploratory laparotomy without resection should be avoided because it delays palliative systemic chemotherapy.
Suspicious lymph nodes beyond the hepatoduodenal ligament should be sent for frozen section. However, preoperative assessment of suspicious aortocaval and truncal lymph nodes with endoscopic ultrasound and fine needle aspiration is preferred. Guidelines recommend to perform a lymphadenectomy in all patients with resectable iCCA. 99 For optimal staging, the 8th edition of the AJCC staging systems recommends to harvest at least six locoregional lymph nodes.
1 It appears that lymphadenectomy is mainly a staging procedure with little effect on OS.
| Perioperative systemic chemotherapy
Systemic chemotherapy with gemcitabine and cisplatin is the standard of care in patients with advanced biliary cancer. 100 The ABC-02
RCT found a superior median OS of 11.7 months with gemcitabine and cisplatin, compared to 8. 
| Outcomes after resection
Post-operative mortality after resection for iCCA depends on both patient and tumour characteristics. A minor liver resection and 19% had a simultaneous intra-and extrahepatic recurrence. 107 Another study of 189 patients found that the initial recurrence within 24 months was only intrahepatic in 54% of patients with a recurrence, compared to 33% after 24 months. 93 Small studies have reported favourable outcomes after resection of recurrence in selected patients.
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The median OS after curative-intent resection is about 30 months with a 5-year OS of about 30% based on several large series. 
| Liver transplantation
Historical series of liver transplantation for unresectable iCCA showed a poor 5-year OS below 25%. 111 Considering these poor outcomes and the scarcity of organs, iCCA has been a contraindication for liver transplantation. A recent series found that cirrhotic patients with uninodular iCCA of less than 2 cm had a similar OS after liver transplantation as matched HCC patients. 112 More recently, highly selected patients with well-differentiated iCCA of less than 2 cm (ie, very early iCCA) had a 5-year OS of 65%. 113 However, both studies apply only to a small proportion of patients with iCCA.
Liver transplantation has also been performed for unresectable iCCA in 12 patients with stable disease on neoadjuvant systemic chemotherapy. 46 Three patients (25%) developed recurrent disease within one year. Living donor liver transplantation may expand the role of transplantation for iCCA. Careful patient selection is needed of patients who are not expected to develop extrahepatic disease within a few years after transplantation.
| Locoregional treatments
Surgical resection is the preferred treatment for resectable iCCA.
However, a lesion of less than 2 or 3 cm located centrally in the liver could be considered for thermal ablation (eg, RFA or MWA) in patients with a high surgical risk (eg, cirrhosis with floxuridine has been investigated in a study of 104 patients. 117 Because floxuridine, which is similar to 5-FU, has a 95% first-pass effect, it can be delivered in the hepatic artery at a very high dose.
The partial response rate was about 60%. Median OS was 31 months compared to 18 months in patients who received systemic chemotherapy alone. Five-year OS was 20% in patients who received HAIP chemotherapy. Although no direct comparison has been performed, the results of HAIP chemotherapy are promising.
| Future research
Future research should improve patient selection for resection of iCCA.
Resection is technically feasible even in patients with multiple lesions or requiring vascular reconstruction. However, a small survival benefit may not justify considerable post-operative mortality, particularly in frail pa- Finally, a minimal-invasive (laparoscopic or robotic) approach may have a modest impact on post-operative complications and recovery, but probably not on survival outcomes.
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